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Background: Anti-malarial drugs are constantly exposed to the threat of evolving drug resistance so good
stewardship of existing therapy is an essential component of public health policy. However, the widespread
availability of numerous different drugs through informal providers could undermine official drug deployment
policies. A policy of multiple first-line therapy (MFT) is compared with the conventional policy of sequential drug
deployment, i.e., where one drug is used until resistance evolves and then replaced by the next drug in the
sequence.
Methods: Population genetic models of drug resistance are used to make the comparison; this methodology
explicitly tracks the genetics of drug resistance (including, importantly, recombination in the sexual stage, intrahost
dynamics, and direction of linkage disequilibrium).
Results: A policy of MFT outlasts sequential application providing drug usages are low to moderate, and appears
not to drive widespread multi-drug resistance. Inadequate dosing is an even more potent driver of drug resistance
than the MFT/sequential policy decision.
Conclusions: The provision of MFT as a deliberate policy can be encouraged provided overall treatment rates are
low or moderate (less than around half of malaria infections are treated) and the ad hoc provision of MFT through
the private sector may be tolerated. This must be fully supported by education to ensure people take adequate
doses of each of the drugs.
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Malaria imposes considerable strains on local health
infrastructures, where well over half of paediatric hos-
pital admission may be attributable to malaria (e.g., [1]),
places significant financial burden on families and indivi-
duals who are not hospitalized [2], and is estimated to
slow national economic growth by around 1.7% per
annum. The provision of effective anti-malarial drugs is
therefore a mainstay of public health policies aimed at
reducing morbidity and mortality [3]. Most countries
now adhere to the mandatory deployment of anti-
malarial drug combinations, invariably in the form of* Correspondence: tra@well.ox.ac.uk
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distribution, and reproduction in any mediumartemisinin combination therapy (ACT), as a means of
delaying the evolution of drug resistance [4,5].
There are currently several effective forms of ACT
based around amodiaquine, lumefantrine, mefloquine,
piperaquine, sulphadoxine-pyrimethamine (where the
latter is still effective) and possibly CQ [6]. Current drug
deployment policies, hereafter termed “sequential”, make
use of a single first-line therapy which is used until the
level of treatment failure rises above an acceptable level
(currently 10% [7]), at which time the drug should be
replaced with a new treatment. An alternative strategy
would be to deliberately deploy multiple first-line ther-
apy (MFT) simultaneously, resulting in malaria infec-
tions being treated with different drugs. WidespreadCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sector may already result in a de facto situation of MFT
in many countries [8].
An innovative evolutionary-epidemiological study [9]
suggested that MFT would result in longer overall peri-
ods of drug effectiveness. This was based on the eco-
logical argument that it is more difficult for organisms
to evolve in a heterogeneous environment caused, in
this case, by different drug treatments, than in a
homogenous treatment environment associated with sin-
gle drug use. This ecological argument is sound but the
study was unable to incorporate three important facets
of malaria epidemiology. Firstly, the threat posed by the
emergence of multi-drug-resistant genotypes. Boni et al.
[9] were prevented, by technical reasons, from an expli-
cit investigation because their methodology assumed
random breeding among malaria parasites within the
whole parasite population. This greatly overestimates the
extent of sexual recombination in the malaria population
because, in reality, recombination can only occur be-
tween malaria clones co-infecting the same human. The
small number of clones in a person (usually one to five)
means self-fertilization is frequent (typically >50%
[10,11]) and, furthermore, only resistant parasites are
present in a person following drug treatment so sexual
breakdown of resistant haplotypes is much lower. Sexual
recombination determines the extent of linkage disequi-
librium (LD), which has long been known as a key driver
of multi-drug resistance [12,13]. LD is such a critical
parameter because if resistance mutations become statis-
tically associated in the same parasites then each resist-
ance mutation essentially ‘hitchhikes’ with the others
because multi-drug-resistant haplotypes can survive
treatment with any drug, enabling multi-drug resistance
to rapidly sweep through a population. The second facet
was to ignore the effects of intrahost dynamics: if a trea-
ted individual contains several malaria clones then drug-
mediated removal of sensitive clones may boost the
transmission of any surviving resistant clones by remov-
ing competition. This is one of the three key drivers of
anti-malarial drug resistance [5,14] also known as ‘com-
petitive release’ [15]. The third facet was the assumption
that an infection met only one drug during its infective
lifespan. The reality in many clinical settings is that
drugs are used presumptively to treat any undiagnosed
fevers and drugs are widely available outside the formal
health service; most non-artemisinin anti-malarial drugs
have long half-lives and persist for weeks after treat-
ment, consequently many patients harbour residual drug
from previous treatments [16,17]. If the residual and
treatment drugs are different (as will frequently occur in
areas utilizing MFT) then the parasites must be resistant
to both drugs: resistance to the residual drug allows the
infection to become established, while resistance to thesecond allows it to survive direct therapy. The policy of
MFT therefore slowly morphs into a de facto policy of
combination therapy (CT) that is known to be a potent
driver of multi-drug resistance. In summary, a worst-
case scenario under MFT is that different resistance
mutations become genetically associated so that multi-
drug-resistant parasites rapidly arise that are fully resist-
ant to all drugs in the MFT arsenal. It is impossible to
recommend the use of MFT without quantifying this
risk especially given the high-profile consequences of
multi-drug resistance in other infections such as tuber-
culosis and Methicillin-resistant Staphylococcus aureus
(MRSA) [18,19].
It is interesting to note that a similar debate is taking
place in bacteriology, where the relative merits of anti-
biotic rotations and mixing are being investigated (see,
for example, [20-22]). Several of the principles are the
same as for malaria treatment but there are important
biological differences that preclude a direct comparison.
Bacteria acquire resistance extremely quickly, and the
main concern in therapy is preventing the de novo emer-
gence of resistance from within a bacterial infection; in
contrast, with the exception of atovaquone, de novo re-
sistance to most anti-malarial drugs occurs extremely in-
frequently. Bacteria also have very different genetics: a
relatively high mutation rate, meiosis is absent so that
genetic recombination is less formalized, and horizontal
gene acquisition may occur.
Herein, an explicit population genetic model is used to
compare the policies of sequential drug use and MFT in
the treatment of malaria and address the key issue of
most contemporary concern to policy makers: the extent
to which they should encourage, tolerate, or even at-
tempt to suppress the parallel deployments of MFTs (in
the same way that they suppress the deployment of arte-
misinins as monotherapy [4]).
The primary purpose of this study is to consider
the risk posed by MFT in driving LD and multi-drug
resistance. However, the methodology was extended
to address several other operational questions omit-
ted from the previous MFT study. Do different clin-
ical/epidemiological settings, which can alter the
genetic basis of resistance, affect the relative advan-
tages of sequential and MFT applications? Is MFT al-
ways the best strategy in all epidemiological settings?
If MFT is to be tried, should it first be trialled in
high or low transmission areas? How does the pres-
ence of intrahost dynamics and competitive release
[14,15,23] affect the results? Would a strategy of full
combination therapy, i.e., combining all available
drugs in a single therapy, be an even better strat-
egy?; it is unlikely that any policy maker would be
brave enough to consider this option, but it provides
a useful theoretical baseline (see later).
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OgaraK [24] was used to carry out the comparisons.
This is a population genetics simulator of the emergence
and spread of drug resistant malaria that incorporates
multiple genetic loci, sexual recombination, LD, differing
levels of multiplicity of infection (MOI, see below) and
different genetic models of how resistance is encoded.
Population genetic models for malaria have to address
several non-standard features of its biology; these are
briefly re-iterated here together with the conventional
assumptions made during their modelling. Malaria para-
sites are haploid and reproduce asexually in humans.
Humans are repeatedly bitten by infected mosquitoes,
which leads to several genetically distinct malaria clones
being present in the blood at any given time. The num-
ber of simultaneous infections in a human is termed the
multiplicity of infection (MOI), which typically ranges
from one to 12. Malaria parasites are briefly sexual and
diploid in the mosquito vector, where they reproduce
sexually in the conventional eukaryote manner, i.e.,
through crossing-over and recombination between chro-
mosomes. Crucially, the sexual phase can only involve
parasites ingested through the same blood meal (mos-
quitoes feed approximately every three days so mating
between parasites in blood meals obtained in separate
bites is assumed to be impossible). It is assumed that
each blood meal is taken from a single human so the
number of mating options inside the mosquito is
dependent on the MOI of the human providing the
blood meal (interrupted feeding followed by the mos-
quito resuming feeding on a different human does occa-
sionally occur but this essentially just increases the MOI
in the meal). This creates an environment which departs
from standard population genetic models, namely a
highly substructured population where mating can only
occur between the small number of different parasite
clones within a blood meal. Sexual union and recombin-
ation between parasites originating from different clones,
‘outcrossing’, results in re-arrangement of genetic mater-
ial and production of progeny with novel genotypes but
recombination between parasites originating from the
same clone, ‘selfing’, results in genetic shuffling of identi-
cal haploid genotypes so the progeny are genetically
identical to the parental clone [25].
Infections are assumed to have equal infectivity and
mate at random inside the mosquito so that if there are
n clones in a human then selfing rate is 1/n and out-
crossing rate is 1-1/n and competitive release [13,23] is
assumed to occur. It was assumed, in common with
most malaria genetic modelling, that parasite clones
were unrelated within humans although recent evidence
suggest this may not always be the case [26]; in this case
the recombination rate between loci, r, needs to be
scaled by the degree of unrelatedness, i.e., r(1-F) where Fis the relatedness of the clones. A crucial difference be-
tween areas of high and low malaria transmission is the
MOI: high malaria inoculation rates in areas of high
transmission intensity leads to higher MOI, so mosqui-
toes frequently ingest unrelated parasites resulting in
increased levels of sexual recombination [27]. MOI is,
therefore, a reflection of transmission intensity.
Different infections may have different drug-resistance
profiles. The genotypes of each infection were simulated
assuming that all loci are physically unlinked, a realistic
assumption for most loci known to encode malaria drug
resistance [28]. A simplifying assumption is also made
that that there is no cross-resistance among drugs (i.e., a
single mutation cannot encode resistance to more than
one drug in the therapeutic arsenal), but note that this is
not applicable to all known cases [29]. Each locus can
have two alleles: resistant and sensitive. Resistant alleles
will incur a fitness penalty if they are not required for
survival [i.e., in untreated hosts, in hosts treated with a
drug for which the mutation cannot encode resistance
or in cases where the epistasis mode (see below) does
not require all mutations]. Parasites in infected humans
may remain untreated (an environment where sensitive
infections are fitter), treated in humans who have little
or no host immunity (where a weaker epistasis mode
suffices to confer resistance), or treated in humans who
are semi-immune to infection (requiring the strong
mode of resistance). Parasite multi-locus genotypes can
vary from sensitive to all drugs to resistant to all drug
treatments available and having all mutations (multi-
resistant).
For all simulation scenarios the fitness penalty asso-
ciated with each resistant mutation and the amount of
drug treatment (defined as the percentage of infected
humans that were treated) were both varied between 0
and 100% in increments of 2%. Genotypes with multiple
mutations incur a multiplicative fitness penalty. Four dif-
ferent MOI scenarios were simulated. Two simple sce-
narios where each human had MOI fixed at two (low
transmission) and four (high transmission). Two more
realistic scenarios were also investigated: one (low trans-
mission) where 50% of human hosts had a single infec-
tion (MOI=1) and the other half had MOI=2, and
another (high transmission) scenario where humans had
MOI described by a Poisson distribution with a condi-
tional mean of 2.3 truncated at a maximum MOI of
seven [23]. The simpler MOI scenarios qualitatively cap-
ture the results of the more complex ones (results not
shown), so only the results from the simple MOI distri-
butions are presented. All these results can easily be
replicated as ogaraK is made publicly available [24] and
can simulate all the scenarios above.
It is assumed that resistance to all therapies exist at
very low frequencies at the onset of the simulation. The
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effectiveness have been studied elsewhere [9,30]. This
approach is complementary as it attempts to understand
the spread, rather than the origin, of existing resistance.
Furthermore resistance to most drugs is now wide-
spread, and has probably emerged also for artemisinins
[31] and in many cases de novo resistance has arrived
in human population via migration [32], not local
mutation.
These analyses of sequential drug deployment did not
allow the option of re-using a drug after all possible
therapies have been exhausted. Fitness costs associated
with resistance may decrease the frequency of the resist-
ance mutation once the drug has been withdrawn to the
extent that a once-failing drug recovers its efficacy and
could, in principle, be re-inserted into the sequence.
This option was not considered because this possibility
is highly dependent on the fitness penalty associated
with the resistance mutation and the length of time
since it has been withdrawn. Fitness effects seem to vary
considerably, the crt locus involved in CQ resistance
seems to incur a higher fitness penalty than the dhfr
mutations associated with sulphadoxine-pyrimethamine
(SP) resistance [33]. The time between replacements in a
sequence may allow the mutation frequency to fall, but
not to its original basal level, so resistance will probably
rapidly spread again from a relatively high basal fre-
quency [6] and it is not operationally feasible for policy
makers to switch drugs over a likely timescale of months
(hence the realization that even if CQ is redeployed in
Malawi, it would be as part of an ACT).
The same caveats apply here as to any modelling study,
primarily that it can only investigate a finite, although
plausible, set of conditions. Policy makers may wish to
develop and refine similar analyses (using ogaraK) specif-
ically calibrated for their own circumstances. A compre-
hensive search of parameter space was conducted to verify
that the conclusions are robust. For instance, most ana-
lyses and discussion was made assuming a range of fitness
penalties per loci. This was carefully scrutinized through
comparisons with simulations with no fitness penalty.
Other assumptions do require future study: (i) if several
different ACTs are used then there is likely to be a par-
tially shared resistance basis (on the artemisinin deriva-
tive) and further work is needed in modelling drugs with
partially shared resistance; (ii) some drugs, notably CQ
and amodiaquine [34], do share the same resistance loci
but the mechanism of resistance seems to be different –
even opposite and (iii) residual drug levels play a critical
role in the emergence and spread of resistance [35] but
have not been formally included except as a factor result-
ing in de facto CT. It is important that policy makers
understand the limitations and assumptions of this (and
any other) models of resistance.The possibility of cross-resistance between drugs or its
converse, resistance “antagonism” (e.g., the pfcrt K76T
mutation which encodes increased resistance to CQ but
increased sensitivity to lumefantrine [36]), is an interest-
ing question. This was not considered explicitly here for
three key reasons. Firstly, it is likely that people design-
ing a policy of MFT would avoid using drugs to which
there was extensive cross-resistance as this, intuitively,
would negate its main advantage in slowing the spread
of resistance. Secondly, the effect would have to be
quantified and there is no guarantee that correlations in
resistance caused by single genes (e.g., [37]) would be
the same as that produced by standing genetic variation
prior to resistance spreading (e.g. [38]). Thirdly, most, if
not all, models of multi-drug resistant malaria ignore the
possibility of cross resistance so the results presented
here are directly comparable to previous work.
An important feature of ogaraK is that when more
than one locus encodes resistance to a single treatment,
it is able to incorporate different epistasis modes among
the resistance loci [13]. It is assumed that two resistance
loci determine resistance to each drug and that two
drugs are deployed so that a resistance genotype consists
of four independent loci. The epistasis modes are as
follows.
‘Full epistasis’: parasites must carry resistant alleles at
both loci to survive treatment by a drug.
‘Duplicate gene function (DGF)’: parasites carrying a
resistance mutation at either locus can survive treatment
by a drug.
‘Mixed mode’: Half of the treated patients have no host
immunity, thus infections will be able to survive treat-
ment if the most important locus has a resistant allele
(asymmetrical epistasis), the other half will be immune,
therefore only parasites that have both resistant alleles
will survive treatment (full epistasis). Asymmetrical epis-
tasis reflects the resistance mechanism observed in both
SP and CQ where the ‘most important’ loci are crt and
dhfr respectively with mdr1 and dhps playing a lesser
role in encoding resistance.
Sequential application, MFTand combination were inves-
tigated using these different modes of epistasis to capture
the clinical/epidemiological variation known to be import-
ant in field conditions. For example, a person who takes a
full drug dosage and/or is semi-immune is a very harsh en-
vironment for parasites and they may require mutations at
all loci to survive (described by ‘Full epistasis’). Conversely,
a patient who takes a sub-optimal dose and/or is non-
immune to malaria constitutes a relatively benign treatment
environment and parasites may survive if they posses only
a resistant mutation at a single locus (described by DGF or
Asymmetrical Epistasis). Full epistasis is deemed a “strong”
mode as it requires all mutations for resistance; conversely
DGF and Asymmetrical Epistasis are called “weak”.
Figure 1 Impact of policy and multiplicity of infection (MOI) on
useful therapeutic life; the latter is plotted on the Y axis and is
defined as the number of parasite generations that elapse
before overall drug failure rates reach 10%. It is plotted as a
function of drug usage (the proportion of infections that are treated)
on the X-axis. The chart compares combination therapy (CT), MFT
and sequential (Seq) deployment policies with MOIs of 2 and 4 and
with a fitness penalty of 10%. MFT and CT perform better than
sequential policies at lower drug usage but MFT marginally worse
with high drug usage. All three deployment policies last longer with
lower MOIs. (A) Two drugs are available. (B) Three drugs are
available; the lines start abruptly because for lower drug usage the
policies last longer than the 200 generations simulated.
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generations (where a generation encompasses one
complete malaria life cycle mosquito→human→mos-
quito); there are likely to be around five generations per
year [39,40] so the simulations last approximately
40 years which easily encompasses the timescales likely
to be considered in long-term planning. In order to
compare policy duration it was assumed that a sequen-
tial policy lasts until the last drug is removed from circu-
lation. A drug is replaced as soon as an average of 10%
of infections are resistant to it. For MFT and combin-
ation therapy it was assumed that a policy stops being
effective as soon as 10% of all infections resist treatment.
This figure of 10% was chosen because the World
Health Organization (WHO) recommends a change of
treatment regimen when cure rate falls below 90% [7].
Results
MFT policies last longer than equivalent sequential pol-
icies for low to medium drug usage (Figure 1). Sequen-
tial application performs better when treatment rates are
high, but in this case the difference between policies is
minor. Varying fitness penalty (including no fitness pen-
alty) has no qualitative effect on these conclusions.
Combination therapy resulted in therapeutic lifespan
very similar to MFT (Figure 1). The fundamental quali-
tative difference between combination therapy and the
other policies is that CT is a strong driver of multiple
drug resistance with frequency of the multi-resistant
genotype usually above 50% at the end of its useful
therapeutic lifespan (Figure 2A). The multi-resistant
genotype is the only one that can resist treatment under
combination therapy so most resistant genotypes are
multi-drug resistant under this deployment policy. Con-
versely, the multi-resistant genotype is never the most fit
in any human hosts under a policy of sequential applica-
tion or MFT because this genotype always pays fitness
costs for carrying resistance mutations to drugs that are
not used to treated the host; consequently multi-drug re-
sistance only becomes frequent, through random genetic
association, when resistance to all drugs is high. This
random process is qualitatively different with low and
high resistance frequencies [13], so the same comparison
was made for a much higher threshold of resistance
(50%) before a drug is removed. Simulations show that
MFT multi-resistant pattern then shifts to an intermedi-
ate between sequential application and combination
therapy (Figure 2B).
Figures 1 and 2 were produced using a full epistasis
mode of resistance but the results are qualitatively simi-
lar for all three epistasis modes (Figure 3). The number
of drugs used does not qualitatively change the results
reported in Figure 1: using more drugs will increase the
useful therapeutic life proportionally for each policy.
Figure 2 The impact of deployment policy on the spread of
multi-drug resistant malaria: the distribution of multi-drug
resistant genotypes at the policies’ end-of-life. MFT and
sequential application show similar patterns where most genotypes
are not multi-resistant. Combination therapy is qualitatively different
as most genotypes at policy end-of-life are multi-resistant. (A) End of
life is assumed to occur at 10% resistance. (B) End of life is assumed
to occur at 50% resistance.
Figure 3 Impact of policy and epistasis on useful therapeutic
life. Policy duration is plotted on the Y-axis and the drug usage on
the X-axis. The chart compares full epistasis with the ‘mixed’ epistatic
mode of resistance for MFT and sequential drug application
assuming a fitness penalty of 10%. The useful therapeutic life always
lasts longer in clinical/epidemiological settings requiring full epistasis
rather than mixed model. (A) Two drugs are available. (B) Three
drugs are available.
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“tipping point” where the advantage of mutations encod-
ing drug resistance is greater than the fitness cost [41],
allowing increased drug usage without significant resist-
ance spread.
Multiplicity of infection is an important factor in de-
termining the length of effective drug use as all policies
last longer with lower MOI (Figure 1). Its impact ismediated by two factors: increasing prevalence of resist-
ance, and the impact of recombination. The “prevalence”
of resistance (the proportion of treated humans with one
or more resistant clones) increases with MOI [13] allow-
ing a higher frequency of resistant genotypes to be trans-
mitted to the next generation though ‘competitive
release’. However, this effect is potentially offset by a
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LD that will occur in high MOI settings.
The spread of resistance is faster in environments with
weak epistasis modes. Figure 3 exemplifies this as both
MFT and sequential application last longer with full
epistasis than with mixed mode. In fact, the modes of
epistasis are more important in determining policy dur-
ation than the policies themselves. In mixed mode, the
main locus is sufficient to confer resistance in half of the
environments treated with a drug so there is no need for
association with a second locus. This is quantitatively
more important if high fitness penalties are associated
with resistance mutations: the second locus encoding re-
sistance to a drug is not needed in half of the drug treat-
ments (in contrast to full epistasis where it is always
needed), therefore it is often deleterious even in the
presence of a drug.
Sexual recombination reduces any statistical associ-
ation (LD) between resistant alleles at different loci. The
frequency of resistance qualitatively influences the im-
pact of recombination. One of the fundamental assump-
tions in any malaria model of resistance is that the
frequency of resistant alleles is less than 50% (as WHO
policies postulate efficacy levels above 90% [7]). If a
clone is resistant to one drug, a recombination event in-
volving a different clone will probably generate offspring
that are only resistant to the same drug, as the other
clone is probably sensitive (due to the assumption of low
frequency of resistance). Linkage disequilibrium patternsFigure 4 Frequency and linkage disequilibrium,(r), with varying policie
penalty of 10%. Each column depicts a different policy (MFT or sequentia
shows the frequency over time of all genotypes: green is the fully sensitive
represent genotypes containing one, two or three resistance mutations. Th
(green) and two loci encoding resistance to different drugs (black). Note thcan change with different epistasis modes and drug pol-
icies. Figure 4 shows the LD (r) for both policies assum-
ing full epistasis or DGF over the whole 200 generations
simulated. Both the signal and magnitude of LD varies
with epistasis and policy: it is positive in full epistasis for
loci involved in resistance to the same drug and negative
for DGF. From an empirical perspective, all signals and
intensities of LD are plausible depending on policy and
epistasis mode [13]. Note that positive LD indicates re-
sistance alleles are found together in the same parasite
genotypes more often than expected by chance, and
negative LD indicates that they are associated less often
than expected.
The fundamental consequences of different drug de-
ployment policies can therefore be summarized on
Table 1 as follows. Sequential Application is character-
ized by medium drug therapeutic lifespans and low
levels of multi-drug resistance. MFT is characterized by
long drug therapeutic lifespans and low levels of multi-
drug resistance. Combination therapy is characterized by
the longest drug therapeutic lifespans but extreme
increases in multi-drug resistance.
Discussion
The key conclusion is that MFT policies last much
longer than sequential application in areas with low to
medium levels of drug usage; sequential deployment is
marginally better once treatment rates become substan-
tial (>~45% in the simulations; Figures 1 and 3). MFT iss and epistasis modes for a drug usage of 30% and fitness
l application) and epistasis mode (full epistasis or DGF). The top row
genotype, red is the fully resistant genotype, and yellow lines
e bottom row plots LD between two loci encoding for the same drug
at the Y scale for LD (r) is different on each column.
Table 1 Summary of the impact of combination therapy,
MFT and sequential application on useful therapeutic life
and the spread of multi-resistant genotypes assuming
drug usage typical in control scenarios
Policy Impact
Sequential application Medium useful therapeutic life
Low multi-drug resistance
MFT Long useful therapeutic life
Low multi-drug resistance
Combination therapy Longest useful therapeutic life
Extreme increase in multi-drug resistance
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moderate to intense transmission because such areas
typically contain a relatively large proportion of semi-
immune individuals able to harbour asymptomatic infec-
tions (repeated infection leads to the development of
clinical immunity [42,43]) meaning that drug treatment
rates will tend to be lower and recombination rates
higher.
MFT and sequential application show similar patterns
of spread for multi-drug resistant genotypes up to the
10% levels of resistance regarded as maximum permis-
sible in WHO policies (with MFT being slightly better).
This is in contrast to the end-of-life profile of com-
bination therapies. However, if the frequency of resist-
ance increases substantially above WHO standards then
the MFT multi-resistance profile shifts considerably
(Figure 2B). Therefore a realistic assessment of the abil-
ity to maintain resistance within WHO policy limits
should be a fundamental decision guideline regarding
the introduction of MFT.
The results are far less favourable to MFT than the
previous analyses by Boni et al. [9]. Their analyses em-
bedded genetics into an overall model of malaria epi-
demiology so had to simplify the analysis of the former.
In particular their treatment of recombination assumed
random mating among parasites whereas it can only ac-
tually occur between clones co-infecting the same
human, and they also ignored the potential impact of
‘competitive release’ (see Background). In addition, their
parameter space assumed many factors were independ-
ent whereas they are actually correlated. Increasing R0,
for example, will increase MOI and hence both the
amount to recombination and level of competitive re-
lease; increasing the fraction of infections treated will
decrease the amount of recombination, and so on. The
present study takes the simpler approach of isolating the
genetic component and ignoring the complexities of the
underlying malaria epidemiology; this has the advantage
of transparency and also avoids the complexity of having
to calibrate the epidemiology, including such factors as
the acquisition of immunity. The key genetic factor inour simulations is MOI, a factor easily measured in the
field, as an external input into the simulations; critically,
MOI determines levels of competitive release and re-
combination, the latter being accurately calculated as
only able to occur between clones taken up by a mos-
quito from the same human, while drug treatment rate
and factors such as natural selection against mutations
are also externally defined. The analysis are probably not
too dissimilar, Boni et al. noting in their Appendix that
“MFT seems to enjoy the broadest advantage when the
cost of resistance is high and the fraction of cases trea-
ted is low”; the first factor, natural selection, is intuitive
(as for example on Figure one of [33]) while the second
is consistent with the results presented here in Figures 1
and 3. The main difference is that MFT was found to be
slightly counter-productive at high levels of drug treat-
ment, a result that can most likely be attributed to the
inclusion of ‘competitive release’ and recombination
being restricted to clones taken up by the same mos-
quito. It is therefore important to note that current con-
trol and elimination agendas are explicitly aimed at
identifying and treating all malaria infections (i.e., se-
verely increasing drug usage) [44] and that the results
regarding useful therapeutic life are partially reversed
with high drug usage (Figures 1 and 3) although the
difference between policies at higher drug usage is
relatively smaller than the difference at low to medium
drug usage.
This strategy of isolating the genetic processes from
malaria epidemiology has the advantages of clearly fo-
cussing on the genetic of resistance (the spread of resist-
ance is, by definition, a genetic process) while not
precluding it being set within an epidemiological con-
text: it simply forces the user to be explicit about how
the epidemiological factors affect the genetic parameters.
As a concrete example, deploying drugs might plausibly
decrease transmission intensity and therefore might de-
crease MOI. This putative reduction in transmission
may also decrease immunity levels which might, depend-
ing on local diagnostics, increase the levels of drug use
as symptomatic infections become more common. The
key point is that all the epidemiological factors need to
be carefully calibrated, validated and converted into gen-
etic parameters before being brought into a larger gen-
etic/epidemiology model. Note also that it is not simply
their initial values that need to specified, but their dy-
namic change in response to drug deployment and
spread of resistance that needs to be specified. It is
highly debatable whether there is sufficient clinical or
field data to calibrate these processes in a compelling
manner, hence the focus here is on the genetics and the
use of summary epidemiological measures such as MOI.
A recent study [45] took almost the opposite ap-
proach: it included immunity but ignored most of the
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tion and, critically, the effects of recombination in the
sexual phase. It mainly focused on time until resistance
emerges in a population and revisited previous work
[46] that used essentially the same technique i.e. survival
probabilities calculated using branching processes based
on negative binomial distributions. As would be expected
intuitively, the probability of a novel resistant mutation
surviving, and hence waiting time until it occurs, is
dependent on their selective advantage (Box two and
Figure two of [46]). Waiting times could therefore be eas-
ily estimated using the explicit genetic model described
above to calculate selective advantages and hence the
probabilities of survival; these are relatively easy to com-
pute or could be estimated from the relationship given in
Box two of [46]. Survival probabilities were not considered
here because it is not certain that resistance will emerge
from within the treated population (immigration may be a
bigger threat [39]) but, more importantly, it is likely that
some level of resistance will already be present to most of
the candidate partner drugs within an MFT, so it is MFT’s
impact in delaying the spread of resistance, compared to a
policy of rotation, that is likely to be the key operational
question.
A distinction should be made between formal policy
(which is currently sequential deployment virtually every-
where) and the pragmatic realities of different countries
and regions. Distribution of designated ACT through the
formal health sector is the official policy in most countries
but the private and informal sectors still distribute numer-
ous types of ACT plus CQ and SP [8], therefore the de
facto reality is likely to be MFT in many areas. The analyses
and results indicate that the MFT approach adopted by the
private sector is unlikely to undermine official drug policy
so there would be little justification for attempting to sup-
press drug distribution through this sector (with the obvi-
ous caveat that distribution of artemisinin monotherapies
and/or ineffective drugs should be suppressed). It should be
noted, however, that intense MFT deployment in some
areas, likely to be urban settings with high levels of informal
drug provision, is likely to change MFT into a de facto pol-
icy of combination therapy (due to long drug half-lives) so
there is a very real of danger of driving local epidemics of
multi-drug resistance malaria in these settings (Figure 2).
Residual drug levels have little impact on sequential pol-
icies because the residual and treatment drugs are assumed
to be the same. They do have an effect in MFT policies as
parasites may have to survive one drug at residual levels,
and survive treatment by another drug, which, as noted
before, constitutes a type of combination therapy. This im-
portant effect has not been explicitly quantified for several
reasons: (i) the proportion of people with residual drug
treatment depends on the overall drug use which consists
of treatment against malaria infection, and of presumptivetreatment of people who have malaria symptoms (e.g.,
fever) but are not actually infected; (ii) presumptive treat-
ment is much more common in high transmission (high
MOI) areas with poor clinical diagnosis, so higher MOI
settings show a positive correlation, and hence confound-
ing, between lower therapeutic drug usage (due to immun-
ity) but higher residual drug levels (due to high
presumptive treatment); (iii) residual drug levels may re-
quire weaker epistatic models than therapeutic drug use;
(iv) recent attempts to improve diagnosis using rapid diag-
nostic tests may greatly reduce presumptive drug use; and
(v) finally, different MFT implementations can alter the
effects of residual drugs: if an MFT implementation can as-
sure that the same individual is always treated with the
same drug (either by tracking each individual treatment
history or, more pragmatically, by having different therap-
ies at different geographical locations) then the impact of
residual drug levels will be much reduced; note however
that such schemes would have to meet the clinical require-
ment that a patient failing treatment would have to be
retreated by a different drug. Consequently an indirect ar-
gument for the effects of residual drugs on MFT is
employed: the difference between MFT and CT was small
and CT was generally slightly better at maximizing thera-
peutic lifespan (e.g., Figure 1) so it is concluded, while not-
ing the threat of multi-drug resistance (Figure 2), that the
fact that MFT may operationally merge into a type of CT
would not undermine its deployment and may even act as
a kind of cost effective way of harnessing the benefits of
CT without the financial and technical penalties of having
to co-formulate drugs into a CT.
Compliance with treatment guidelines is fundamental
to delay the spread of drug resistance. Different epistasis
modes were interpreted as reflecting varying immunity
profiles, but epistasis can also reflect treatment compli-
ance [13]. Full compliance is represented by strong epis-
tasis (full treatment forces the parasite to have all
resistant alleles in order to survive) and poor compliance
is represented by weaker epistasis modes. Figure 3
clearly shows that stronger epistasis (full compliance)
allows both policies to last longer. The model provides
strong support for the importance of ensuring proper
dosing and compliance to slow the spread of drug resist-
ance. An inherent drawback of MFT is a possible prolif-
eration of packaging with subsequent confusion over
regimens. As a plausible example, if three drugs are used
in an MFT, each drug is supplied by two manufactures,
and there are four dosing regimens for each drug (one
adult and three paediatric), this makes 24 packages in
total; the dosing regimens may also differ (two treat-
ments per day for artemether-lumefantrine, once per
day for most other ACT). There is clearly considerable
scope for confusion so it is therefore strongly re-
commended that any deliberate policy of MFT be
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sure adequate dosing to offset the threat of resistance.
Conclusions
MFT out-performs the standard policy of sequential ap-
plication for realistic model parameters provided treat-
ment rates are less than about 50%, thereafter MFT
performs slightly worse than other policies. The results
suggest that the impact of MFT on the spread of mul-
tiple resistant genotypes is negligible or even slightly bet-
ter than sequential application as long as resistance is in
within WHO guidelines. An important conclusion is that
widespread availability of multiple ACT through the
informal sector is not an immediate cause for alarm
(although artemisinin monotherapies or low quality
drugs should definitely be suppressed) and that countries
may reasonably choose to deliberately employ a policy of
MFT within the public health sector.
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